Toronto, ON – June 20, 2025 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has filed a preliminary short form base shelf prospectus (the “Prospectus”) to provide the Company with the flexibility to take advantage of financing opportunities and favourable market conditions, if and when needed, during the 25-month period that the Prospectus, once made final, remains effective (the “Effective Period”). A copy of the Prospectus may be obtained under the Company’s SEDAR+ profile at www.sedarplus.ca.
The Prospectus has been filed in each of the provinces and territories in Canada. The Prospectus, when final and effective, will enable the Company to offer, issue and sell, from time to time, common shares, warrants, units, subscription receipts, debt securities, or any combination of such securities (collectively, “Securities”) for up to an aggregate offering price of C$50,000,000, in one or more transactions during the Effective Period.
The Company may also use the Prospectus in connection with an “at-the-market distribution” in accordance with applicable securities laws, which would permit the Securities to be sold on behalf of the Company through the Canadian Securities Exchange (the “CSE”) (or other existing trading markets) as further described in the applicable prospectus supplement. To date, no agreement has been entered into with respect to such a distribution.
PharmAla currently has no immediate plans to issue any Securities under the Prospectus at this time and may never proceed with any such issuance. Should the Company decide to offer Securities, the specific terms, including the use of proceeds, will be set forth in a prospectus supplement to the final base shelf prospectus, which will be filed with the applicable Canadian securities regulators.
“We are excited to announce the filing of our Prospectus as we believe it will serve to support our growth strategy and development of our novel molecules,” said Nick Kadysh, Founding CEO, PharmAla. “It also provides opportunity for not just retail, but institutional investors who are passionate about the potential of MDMA and MDXX molecules to improve health care to participate in future offerings.”
PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.
Nicholas Kadysh, CEO
press@pharmala.ca